Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Medicinal Chemistry

Volumn 10, Issue 3, 2014, Pages 304-317

  Zhang, Lingyu ^a,b   Wang, Yuli ^b   Xu, Huaqiang ^a,b   Shi, Yongheng ^b,c   Liu, Bingni ^b   Wei, Qunchao ^b   Xu, Weiren ^b,c   Tang, Lida ^b,c   Wang, Jianwu ^a   Zhao, Guilong ^b  

^a SHANDONG UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Dapagliflozin; Deoxy; SGLT2 inhibitor; Synthesis

Indexed keywords

6 DEOXYDAPAGLIFLOZIN; DAPAGLIFLOZIN; GLUCOSE; HYDROXYL GROUP; SODIUM GLUCOSE COTRANSPORTER; UNCLASSIFIED DRUG; 1-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1,6-DIDEOXYGLUCOPYRANOSE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; IC 50; IN VITRO STUDY; MONODEOXYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DEOXYGLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; RATS; SODIUM-GLUCOSE TRANSPORTER 2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898739600     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/15734064113096660051     Document Type: Article

References (19)

1. Porte, D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab. Res. Rev., 2001, 17, 181-8.
2. Kikkawa, R. Chronic complications in diabetes mellitus. Br. J. Nutr., 2000, 84, S183-5.
3. Xiao, X.; Wang, P.; Chou, K. C. Recent progresses in identifying nuclear receptors and their families. Curr. Top. Med. Chem., 2013, 13, 1192-200.
4. Chou, K. C. Molecular therapeutic target for type-2 diabetes. J. Proteome Res., 2004, 3, 1284-8.
5. Washburn, W. N. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J. Med. Chem., 2009, 52, 1785-94.
6. Hardman, T. C.; Dubrey, S. W. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther., 2011, 2, 133-45.
7. Meng, M.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller, S. A.; Zahler, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.; Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.; Khanna, A.; Discenza, L.; Robertson, J. M.; Wang, A.; Han, S.; Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.; Washburn, W. N. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2008, 51, 1145-9.
8. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanishi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K. and Tsuda-Tsukimoto, M. Discovery of canagliflozin, a novel Cglucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem., 2010, 53, 6355-60.
9. Ch, R.; Tyagi, M.; Patil, P. R.; Kartha, K. P. R. DABCO: an efficient promoter for the acetylation of carbohydrates and other substances under solvent-free conditions. Tetrahedron Lett., 2011, 52, 5841-6.
10. Zhao, G.; Lou, Y.; Zhang, L.; Shao, H.; Xu, W.; Tang, L.; Zou, M. Total synthesis of α-elvucitabine. Synth. Commun., 2012, 42, 2885-93.
11. Diaz, M.; Ferrero, M.; Fernandez, S.; Gotor, V. 6-s-cis locked analogues of the steroid hormone 1α, 25-dihydroxyvitamin D3. Synthesis of novel A-ring stereoisomeric 1,25-dihydroxy-3-epi-19-norprevitamin D3 derivatives. J. Org. Chem., 2000, 65, 5647-52.
12. Asim, M.; Klonowska, D.; Choueiri, C.; Korobkov, I.; Durst, T.; Carlson, K. E.; Katzenellenbogen, J. A. BC-spiro-estradiols. Synthesis and estrogen receptor binding affinity of four new estradiol isomers. Bioorg. Med. Chem. Lett., 2012, 22, 3713-7.
13. Verma, P.; Kabra, V. K.; Mukhopadhyay, B. Synthesis of two trisaccharides related to the triterpenoid saponins isolated from Solanum lycocarpum. Carbohydr. Res., 2011, 346, 2342-7.
14. Trost, B. M.; Gunzner, J. L.; Dirat, O.; Rhee, Y. H. Callipeltoside A: total synthesis, assignment of the absolute and relative configuration, and evaluation of synthetic analogues. J. Am. Chem. Soc., 2002, 124, 10396-415.
15. Postema, M. H. D.; Calimente, D. Convergent preparation of 1,6- linked C-disaccharides via olefin metathesis. Tetrahedron Lett., 1999, 40, 4755-60.
16. Postema, M. H. D.; Calimente, D.; Liu, L.; Behrmann, T. L. An olefin metathesis route for the preparation of (1→6)-linked Cdisaccharide glycals. A convergent and flexible approach to Csaccharide synthesis. J. Org. Chem., 2000, 65, 6061-8.
17. Xu, B.; Feng, Y.; Lv, B.; Xu, G.; Zhang, L.; Du, J.; Peng, K.; Xu, M.; Dong, J.; Zhang, W.; Zhang, T.; Zhu, L.; Ding, H.; Sheng, Z.; Welihinda, A.; Seed, B.; Chen, Y. ortho-Substituted Carylglucosides as highly potent and selective renal sodiumdependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg. Med. Chem., 2010, 18, 4422-32.
18. Imamura, M.; Nakanishi, K.; Suzuki, T., Ikegai, K.; Shiraki, R.; Ogiyama, T.; Murakami, T.; Kurosaki, E.; Noda, A.; Kobayashi, Y.; Yokota, M.; Koide, T.; Kosakai, K.; Ohkura, Y.; Takeuchi, M.; Tomiyama, H.; Ohta, M. Discovery of ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem., 2012, 20, 3263-79.
19. Goodwin, N. C.; Mabon, R.; Harrison, B. A.; Shadoan, M. K.; Almstead, Z. Y.; Xie, Y.; Healy, J.; Buhring, L. M.; DaCosta, C. M.; Bardenhagen, J.; Mseeh, F.; Liu, Q.; Nouraldeen, A.; Wilson, A. G. E.; Kimball, S. D.; Powell, D. R.; Rawlins, D. B. Novel Lxylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J. Med. Chem., 2009, 52(20), 6201-4.